

Bit Market Services

Informazione Regolamentata n. 0696-119-2015	Data/Ora Ricezione 02 Ottobre 2015 23:26:52	MTA
---	---	-----

Societa' : CTI BIOPHARMA
Identificativo : 63856
Informazione
Regolamentata
Nome utilizzatore : CELLN02 - Villa
Tipologia : IRAG 10
Data/Ora Ricezione : 02 Ottobre 2015 23:26:52
Data/Ora Inizio : 02 Ottobre 2015 23:45:21
Diffusione presunta
Oggetto : CTI BIOPHARMA FILES FORM 8-K

Testo del comunicato

Vedi allegato.



CTI BIOPHARMA FILES FORM 8-K

SEATTLE, Wash., October 2, 2015—CTI BioPharma Corp. (“CTI BioPharma”) (MTA: CTIC) today announced it has filed a Form 8-K with the U.S. Securities and Exchange Commission (“SEC”). A summary of information in the Form 8-K is as follows:

As previously disclosed in the Quarterly Report on Form 10-Q for the quarter ended June 30, 2015 filed by CTI BioPharma with the SEC on August 6, 2015, CTI BioPharma and its directors entered into a memorandum of understanding on May 13, 2015 to settle the shareholder derivative action titled *Lopez & Soper v. Nudelman, et al.*, Case No. 14-2-18941-9 SEA, pending in the Superior Court of the State of Washington, King County (the “Court”). On September 25, 2015, the Court issued an order granting preliminary approval to the proposed settlement. The Court has scheduled a hearing on December 10, 2015 to determine, among other things, whether it should issue an order for final approval of the proposed settlement.

For more detailed information, please refer to the Current Report on Form 8-K that has been filed with the SEC and is available on the SEC website at www.sec.gov, as well as CTI BioPharma’s website at www.ctibiopharma.com

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of CTI BioPharma’s securities. Such statements include, but are not limited to, statements regarding the potential approval of the proposed settlement for the pending shareholder derivative action and the development of CTI BioPharma. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and are based on assumptions about many important factors and information currently available to us. Risks that contribute to the uncertain nature of the forward-looking statements include, among others, risks that the aforementioned settlement will not be approved and risks associated with the biopharmaceutical industry in general and with CTI BioPharma and its product and product candidate portfolio in particular, as well as other risks listed or described from time to time in CTI BioPharma’s most recent filings with the SEC on Forms 10-K, 10-Q and 8-K. Except as required by law, CTI BioPharma undertakes to update its forward-looking statements.

Source: CTI BioPharma Corp.

Contacts:

Monique Greer
+1 206-272-4343
mgreer@ctibiopharma.com

Ed Bell
+1 206-272-4345
ebell@ctibiopharma.com

Fine Comunicato n.0696-119

Numero di Pagine: 3